MARKI MEYER: Open Payments
NPI 1710636394 · VENTURA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,354 in 59 payments from 21 companies in 2025. Trend: 2023 $3,234 · 2024 $3,097 · 2025 $1,354
Food & beverage: $1,354
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 15 | $235 |
| BETA BIONICS, INC. | 6 | $164 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $153 |
| Dexcom, Inc. | 3 | $117 |
| Mannkind Corporation | 4 | $80 |
| SANOFI-AVENTIS U.S. LLC | 2 | $66 |
| Lilly USA, LLC | 3 | $66 |
| RECORDATI_RARE_DISEASES_INC. | 2 | $64 |
| Amphastar Pharmaceuticals, Inc. | 2 | $49 |
| Xeris Pharmaceuticals, Inc. | 2 | $41 |
Products named: JARDIANCE, Ozempic, iLet Bionic Pancreas, Dexcom G6 Transmitter, AFREZZA, TZIELD, GVOKE HYPOPEN, AZMIRO.
Industry payments across CA — which companies pay providers there.
